Germany Cardiovascular Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The germany cardiovascular devices market size is expected to grow from USD 4.03 billion in 2025 to USD 4.31 billion in 2026 and is forecast to reach USD 6.05 billion by 2031 at 7.02% CAGR over 2026-2031. This report Segments the Industry by Device Type (Diagnostic and Monitoring Devices [Electrocardiogram (ECG) and More], Therapeutic and Surgical Devices [Cardiac Assist Devices and More]), Application (Coronary Artery Disease, and More), and End User (Hospitals and More). The Market Forecasts are Provided in Terms of Value (USD).

Germany Cardiovascular Devices Market Trends and Insights

Rapid Expansion of Reimbursed Cardiovascular Procedures

Germany’s DRG system rewards hospitals for interventional care, lifting procedure counts for transcatheter aortic valve implantation beyond 100,000 cumulative cases. Catheter laboratories continue to replace surgical suites, and reimbursement parity between valve surgery and TAVI compresses payback periods for capital equipment. As 95% of octogenarian patients now receive TAVI, device makers bundle valves with embolic-protection filters to enlarge average selling prices while helping hospitals meet stroke-reduction quality metrics

Mandatory Remote Heart-Failure Telemonitoring

Since 2023, statutory insurers must cover remote telemetry for chronic heart-failure patients, motivating adoption of implantable loop recorders and non-invasive hemodynamic sensors. University centers have established command hubs that analyze continuous data feeds and trigger early outpatient interventions, cutting readmissions and freeing inpatient beds. Vendors offer subscription packages that integrate hardware, analytics dashboards, and reimbursement coding support, encouraging hospitals to migrate from episodic follow-up to always-on monitoring workflows.

EU-MDR Post-Market Costs

The 2021 MDR raised evidence thresholds and introduced intensive post-market surveillance, raising recertification costs by up to 300% for some small firms. With only 43 notified bodies to assess 500,000 devices EU-wide, certification queues stretch into 2026. Many German SMEs drop low-volume catheters rather than fund new trials, consolidating purchasing toward large multinationals and reducing product variety for niche applications.

Other drivers and restraints analyzed in the detailed report include:

• Germany’s Highest PCI per-Capita Rate Sustains Drug-Eluting-Stent & Guidewire Replacement Cycles
• Krankenhaus-Zukunft Act Spurs Digital ICU/OR Hemodynamic-Monitoring Upgrades
• Pharmacotherapy Advances Moderating Device Demand

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Therapeutic and Surgical Devices captured 68.55% Germany cardiovascular devices market share in 2025, boosted by 164 TAVI cases per million residents. Growing reliance on drug-eluting stents, left-atrial appendage occluders, and VADs underscores hospitals’ preference for minimally invasive solutions that shorten intensive-care occupancy. Despite the maturity of percutaneous coronary intervention, high-risk subsets such as calcified lesions sustain demand for lithotripsy catheters reimbursed under new OPS codes.

Diagnostic and Monitoring Devices, although smaller, will expand at 6.12% CAGR to 2031, buoyed by AI-driven ECG analytics and mandatory heart-failure telemonitoring.

Complete Report Scope:

• By Device Type
  • Diagnostic & Monitoring Devices
    • ECG Systems
    • Remote Cardiac Monitor
    • Cardiac MRI
    • Cardiac CT
    • Echocardiography / Ultrasound
    • Fractional Flow Reserve (FFR) Systems
  • Therapeutic & Surgical Devices
    • Coronary Stents
      • Drug-Eluting Stents
      • Bare-Metal Stents
      • Bioresorbable Stents
    • Catheters
      • PTCA Balloon Catheters
      • IVUS/OCT Catheters
    • Cardiac Rhythm Management
      • Pacemakers
      • Implantable Cardioverter Defibrillators
      • Cardiac Resynchronization Therapy Devices
    • Heart Valves
      • TAVR/TAVI
      • Mechanical Valves
      • Tissue/Bioprosthetic Valves
    • Ventricular Assist Devices
    • Artificial Hearts
    • Grafts & Patches
    • Other Cardiovascular Surgical Devices
• By Application
  • Coronary Artery Disease
  • Arrhythmia
  • Heart Failure
  • Structural Heart Disease
  • Hypertension
  • Others
• By End User
  • Hospitals
  • Home-Care Settings
  • Others

List of Companies Covered in this Report:

• Abbott Laboratories
• B. Braun
• BIOTRONIK
• Boston Scientific
• CardioFocus Inc.
• Dragerwerk
• Edwards Lifesciences Corp.
• GE HealthCare Technologies Inc.
• Getinge AB (Maquet Cardiopulmonary)
• Lepu Medical
• LivaNova
• Medtronic
• MicroPort Scientific Corp.
• Koninklijke Philips
• Schiller
• Siemens Healthineers
• Straub Medical
• Terumo Corp.
• W. L. Gore & Associates
• Zoll Medical Corp.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support